NEWS

Wang Wenyan

Release time:

2018-06-08 17:24

Education:

Master of Chemical Biology, Fudan University

Bachelor of Applied Chemistry, Inner Mongolia University

 

Experience:

Hua Xun Research Department-R & D Manager and Senior Patent Analyst

Researcher, Yip's Chemical R & D (Shanghai) Co., Ltd.

南京华讯知识产权顾问有限公司

 

Areas of expertise:

Including medical devices, medicine, chemistry, chemical industry, materials, etc., familiar with patent applications in the field, patent search, analysis and invalidation, able to skillfully use Chinese, English, patent search and analysis.

Possess a Chinese patent agent qualification certificate.

 

Representative cases:

Company Project Name Drug use invalid patent Invalid Start Date Briefing
AstraZeneca Astrazeneca BRILINTA(Ticagrelor Tablet) Brilinda (ticagrelor Tablet) for acute coronary syndrome   Application Number Application Date 2015.3 The invalidation process began in March 2015 and the parties reached a settlement in October 2015 (the patentee allowed Huaxun to license this right to a company).
Patent 1 01810582.3 2001.5.31
Patent II 200610002509.5 2001.5.31
Boehringer Ingelheim (Boehringer-Ingelheim) 恩格列净Empagliflozin（Jardiance） Suitable for the treatment of type 2 diabetes   Application Number Application Date 2017.2 In February 2017, the invalidation procedure began. After the oral examination procedure, the re-examination board declared that all three patents were partially invalid.
Patent 1 201310368328.4 2005.3.11
Patent II 201310379906.4 2005.3.11
Patent III 201310414119.9   2005.3.11

 

Published articles:

1.Quantitative research of histone H3 acetylation levels of human hepatocellular carcinoma cells Bioanalysis (IF:3.223)

2. Microchip-based strategy for enrichment of acetylated proteins Microchimica acta (IF:3.033)